A Phase I/II, Multicenter, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Cobimetinib In Pediatric and Young Adult Patients With Previously Treated Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Cobimetinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Acronyms iMATRIX Cobi
- Sponsors Roche
- 16 Mar 2017 Planned End Date changed from 1 Feb 2023 to 28 Feb 2023.
- 16 Mar 2017 Planned primary completion date changed from 1 Feb 2023 to 28 Feb 2023.
- 01 Jul 2016 Planned End Date changed from 1 Jan 2023 to 1 Feb 2023.